Add time:08/12/2019         Source:sciencedirect.com

Aim To compare the efficacy of a new application form of hydrocortisone 17-butyrate (H17-B), 0.1% topical emulsion (Locoid Crelo®) with that of betamethasone 17-valerate (BMV) 0.1% scalp lotion (Betnovate® lotion).Methods Erythema, induration, scaling, pruritus and overall severity of the disease were assessed in 136 patients with moderately severe psoriasis of the scalp at the start and after two and four weeks of therapy. In addition, the effect of the Crelo® steroid-free vehicle was assessed in 12 other patients by dry dermoscopy and squamometry.Results Although both treatments induced a prominent overall improvement, this improvement was significantly better in the H17-B-treated group. H17-B emulsion was superior in the reduction of scaling and overall severity after two weeks, and reduction of scaling, induration, overall severity and total symptom score after four weeks. Cosmetic acceptability also favoured H17-B emulsion. This is probably related to the emollient effect which was shown after a one-week treatment with the steroid free emulsion alone.Conclusion The innovative H17-B emuslion is an efficient addition to topical corticosteroid therapy of psoriasis; it is especially suitable for the treatment of the scalp and other hairy parts of the body.

We also recommend Trading Suppliers and Manufacturers of Locoid C (cas 135467-84-4). Pls Click Website Link as below: cas 135467-84-4 suppliers